Smartwatch Paroxysmal Arrhythmia Detection Compared With Holter

Status Not yet recruiting

Clinical Trial Summary

The lifetime risk for development of atrial fibrillation, the commonest sustained arrhythmia in adults, is estimated to be 24%-27% for individuals of 40 years or older. Previous work showed that annual new diagnosis of AF is 11000-26000 in Hong Kong. Other arrhythmia such as supraventricular arrhythmia or premature beats were also common and of clinical significance. 12-lead ECG is a first line investigation for patients with suspected paroxysmal arrhythmia, but it has a low diagnostic yield with its 10-30 seconds recordings. 24-hour Holter exam is the usual next step of diagnosis. The diagnostic yield of Holter varies according to indication but is generally low at 1%-12%. This is because paroxysmal arrhythmia may not happen every day. In addition, even if arrhythmia is picked up in Holter, patient may not register the symptom, making the symptom arrhythmia correlation problematic. Despite limitations, the demand for Holter exam is still high. In Prince of Wales Hospital, a tertiary referral centre with a catchment of about 1 million populations, the waiting time for a routine Holter exam is 3 years. Smartwatch has gained popularity over past years as an adjunct to smartphone. Latest generations of smartwatch were equipped with wearer-initiated ECG rhythm strip recording capabilities. Smartwatch has evolved to become a health tracker with arrhythmia detection capabilities. It was found to be a useful tool for atrial fibrillation screening in general population. Other arrhythmias, such as supraventricular tachycardia, premature beats, and abnormal ECG patterns associated with sudden cardiac death could also be detected with smartwatch ECG recordings. Apple Heart study was the largest study utilizing smartwatch for arrhythmia detection. The general population was screened for atrial fibrillation using irregular pulse algorithm. The study found a 84% concordance rate between irregular pulse notification and ECG patches. Therefore, investigators propose to conduct a study to compare its diagnostic yield with Holter, in patients with suspected arrhythmia and see if smartwatch recording following a systematic protocol for four-weeks will have better arrhythmia diagnosis yield than a 24-hour Holter exam.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06425887
Study type	Observational
Source	Chinese University of Hong Kong
Contact
Status	Not yet recruiting
Phase
Start date	July 1, 2024
Completion date	July 1, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00376532` - Extracellular Matrix Marker of Arrhythmia Risk (EMMA)	N/A
Recruiting	`NCT04848844` - The PAtients pResenTing With COngenital HeaRt DIseAse Register (ARTORIA-R)
Completed	`NCT06039397` - The Effect of Semi Fowler 30' Right Lateral on Cardiac Output in Acute Heart Failure	N/A
Completed	`NCT04025762` - 24/7 Closed-loop in Older Subjects With Type 1 Diabetes	N/A
Not yet recruiting	`NCT03619018` - All Inclusive KODEX - EPD™ Study Patient Specific Optimized Therapy (PSOT) Study
Completed	`NCT03786640` - Abbott Brady 3T MRI PMCF
Recruiting	`NCT05932602` - AVEIR DR Coverage With Evidence Development (CED) Study
Recruiting	`NCT05935007` - Aveir DR Real-World Evidence Post-Approval Study
Recruiting	`NCT01988064` - Face to Face vs. Group Training Methods on Pulse Rate Taking in Patients With Cardiovascular Diseases.	N/A
Recruiting	`NCT06310707` - Arrhythmia Identification in Syncope Patients: ePatch® Versus 24h Holter	N/A
Terminated	`NCT03481413` - Patient Specific Optimized Therapy Post-Market Clinical Follow-up Study
Recruiting	`NCT05443321` - Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes	N/A
Recruiting	`NCT03801681` - ARrhythmias in MYocarditis
Completed	`NCT03628534` - SERF VT Ablation Early Feasibility Study (EFS)	N/A
Recruiting	`NCT05034432` - The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients	Phase 4
Recruiting	`NCT04856267` - Exploration of Arrhythmia Burden in Cardiac Amyloidosis Using Implantable Loop Recorders
Not yet recruiting	`NCT06414447` - Electrocardiogram (ECG) Validation Study
Completed	`NCT02401659` - Importance of Patient´s Satisfaction With Telemedicine Based on Monitoring Systems	N/A
Recruiting	`NCT05790642` - Comparison of Different Non-invasive Methods to Assess Pulse Wave Analysis
Recruiting	`NCT04833712` - Stereotactic Radioablation for the Treatment of Refractory Atrial Fibrillation	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.